CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation
Pharmacogenomics , Volume 19 - Issue 11 p. 895- 903
Aim: To investigate the association between donor CYP3A5 and ABCB1 polymorphisms and tacrolimus (Tac)-induced nephrotoxicity and renal function in kidney transplant recipients. Methods: The CYP3A5 6986A>G and ABCB1 3435C>T polymorphisms were determined in 237 recipients and donors. Results: There was no significant association between Tac-related nephrotoxicity and donor CYP3A5 and ABCB1 genotype. The donor ABCB1 3435C>T polymorphism was associated with estimated glomerular filtration rate on day 7 and month 1. The combined donor-recipient ABCB1 genotype (3435C>T polymorphism) was significantly related with estimated glomerular filtration rate on day 3 and 7 in univariate analysis. However, these differences were no longer statistically significant in multivariate analysis. Conclusion: A genetic analysis of ABCB1 and CYP3A5 of kidney transplant donors is not helpful to improve renal transplant outcomes.
|, , , , , , ,|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Yang, L. (Lin), de Winter, B.C.M, van Schaik, R.H.N, Xie, R.-X. (Rui-Xiang), Li, Y. (Yi), Andrews, L.M, … Hesselink, D.A. (2018). CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation. Pharmacogenomics, 19(11), 895–903. doi:10.2217/pgs-2018-0066